DaVita Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Javier J. Rodriguez
- Full Time Employees
- 78,000
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2000 16th Street Denver CO United States of America 80202
- IPO Date
- Oct 31, 1995
- CIK
- 0000927066
- Website
- davita.com
- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Company News
3 Surging Stocks That Don't Need the AI Boom to Keep Winning
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You
A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
Do Options Traders Know Something About DaVita Stock We Don't?
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Alebund Pharmaceuticals Announces 2026 Interim Results
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
2,460,987 Shares in DaVita Inc. $DVA Purchased by BlackRock Inc.
Bank of New York Mellon Corp Makes New $101.13 Million Investment in DaVita Inc. $DVA
Bank of America Corp DE Cuts Holdings in DaVita Inc. $DVA
Is DaVita (DVA) a Great Value Stock Right Now?
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
Dow Extends Record Run With Over 400-Point Pop
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita Q2 Earnings Call Highlights